ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for smarter Trade smarter, not harder: Unleash your inner pro with our toolkit and live discussions.

OCGN Ocugen Inc

1.775
0.055 (3.20%)
Last Updated: 12:08:58
Delayed by 15 minutes
Share Name Share Symbol Market Stock Type
Ocugen Inc OCGN NASDAQ Common Stock
  Price Change Price Change % Share Price Last Trade
0.055 3.20% 1.775 12:08:58
Open Price Low Price High Price Close Price Previous Close
1.75 1.68 1.82 1.72
more quote information »

Recent News

Date Time Source Heading
5/20/202406:00GLOBEOcugen Announces CSO to Present on Modifier Gene Therapy..
5/17/202415:30EDGAR2Form PRE 14A - Other preliminary proxy statements
5/15/202405:30GLOBEOcugen Announces Dosing Completion of Subjects with..
5/14/202414:54EDGAR2Form 8-K - Current report
5/14/202407:00GLOBEOcugen Provides Business Update with First Quarter 2024..
5/14/202406:18IHMARKETNEWSUS Futures Remain Steady Amid Wall Street Caution Ahead of..
5/14/202405:32EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
5/10/202415:15EDGAR2Form 8-A12G - Registration of securities [Section 12(g)]
5/10/202415:14EDGAR2Form 8-K - Current report
5/10/202415:05GLOBEOcugen Announces Distribution of Series C Preferred Stock to..
5/10/202406:45GLOBEOcugen to Present at May 2024 Investor Conferences
5/03/202406:30GLOBEOcugen to Host Conference Call on Tuesday, May 14 at 8:30..
5/02/202406:15GLOBEOcugen Announces CSO to Present on Modifier Gene Therapy at..
4/29/202405:45GLOBEOcugen Announces OCU400—Modifier Gene Therapy—Phase 1/2 Data..
4/26/202408:05GLOBEUPDATE -- Ocugen to Present on Modifier Gene Therapy..
4/26/202405:30GLOBEOcugen to Present on Modifier Gene Therapy Platform at..
4/19/202406:13GLOBEOcugen Announces Dosing Completion of Subjects with..
4/12/202406:30GLOBEOcugen to Participate in Fireside Chat at the Emerging..
4/10/202406:02GLOBEOcugen, Inc. Announces Positive Scientific Advice from the..
4/08/202405:30GLOBEOcugen, Inc. Announces U.S. FDA Clearance of IND Amendment..
4/05/202406:02GLOBEOcugen Announces Positive Data and Safety Monitoring Board..
4/02/202407:00GLOBEOcugen Provides Business Update with Certain Financials for..
4/01/202417:08GLOBEOcugen Announces Positive Data and Safety Monitoring Board..
4/01/202416:43GLOBEOcugen to Host Conference Call on Tuesday, April 2 at 8:30..
3/18/202405:30GLOBEOcugen, Inc. Appoints Huma Qamar, MD, MPH as Chief Medical..
3/13/202407:00GLOBEOcugen, Inc. Announces Dosing Completion of Subjects with..
3/06/202406:30GLOBEOcugen to Present at Investing in Cures Summit
2/28/202407:00GLOBEOcugen Clinical Showcase Webcast Now Available
2/26/202407:30GLOBEOcugen Chairman and CEO to present at Abu Dhabi Family..
2/22/202415:05GLOBEOcugen, Inc. Announces Dosing Completion of Subjects with..
2/21/202415:05GLOBEOcugen to Present at 2024 BIO CEO & Investor Conference
2/21/202410:22EDGAR2Form 8-K - Current report
2/14/202406:30GLOBEOcugen to Host Clinical Showcase in New York City..
1/31/202407:00GLOBEOcugen to Present at Pharma Market Research Conference
1/16/202406:30GLOBEOcugen, Inc. Announces Bob Smith Joins Business Advisory..
1/08/202405:05EDGAR2Form 8-K - Current report
1/05/202415:47EDGAR2Form 4 - Statement of changes in beneficial ownership of..
1/05/202415:47EDGAR2Form 4 - Statement of changes in beneficial ownership of..
1/04/202416:05EDGAR2Form 4 - Statement of changes in beneficial ownership of..
1/04/202416:04EDGAR2Form 4 - Statement of changes in beneficial ownership of..
12/22/202314:09EDGAR2Form 8-K - Current report
12/21/202305:30GLOBEOcugen Gains FDA Alignment on Key Aspects of OCU400—Modifier..
12/19/202306:30GLOBEOcugen Announces OCU400 Receives Regenerative Medicine..
12/13/202306:30GLOBEOcugen, Inc. Announces First Patient Dosed in Phase 1/2..
11/29/202306:30GLOBEOcugen CEO to Present at NobleCon19 – Noble Capital Markets’..
11/10/202306:30GLOBEOcugen, Inc. Announces First Patient Dosed in Phase 1/2..
11/09/202307:02EDGAR2Form 8-K - Current report
11/09/202306:02EDGAR2Form 8-K - Current report
11/09/202305:30GLOBEOcugen Provides Business Update with Third Quarter 2023..
11/09/202305:05EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]